Biopharma Food and Drug Administration Specialization 
Pharmaceutical Technology
OCTOBER 3, 2022
Myovant Sciences has rejected an acquisition offer worth $2.5bn from Sumitovant Biopharma and its wholly-owned subsidiary Sumitomo Pharma, citing it 'significantly undervalues' the company. The board of directors of Myovant constituted a special committee of independent directors including its audit committee members to assess the proposal.
Clarivate
MAY 24, 2023
Food and Drug Administration advisory committee’s narrow 8-6 vote in favor of recommending accelerated approval for a first-in-class gene transfer therapy was welcomed by Duchenne muscular dystrophy (DMD) patients and caregivers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
MAY 24, 2022
Recent policy and regulatory moves have begun to sketch out a framework for rare disease drug approvals in the country, but obstacles to approvals and patient access remain. The list, designed to serve as a reference point for prioritized drug review and evaluation policies, included 121 rare diseases. [8]. 10] [11] [12].
MedCity News
JUNE 16, 2023
Investors in 2022 appeared confident that the continued transformation of drug research and development protocols and the overall life sciences industry will not only include digital health solutions, but will even depend on them for data collection, analysis, patient engagement, and even their therapeutic properties.
Pharmaceutical Technology
APRIL 24, 2023
These attributes make some biologic drugs, especially monoclonal antibodies more specific and targeted in their treatment. With new drugs on the market, companies are now looking for ways to manufacture recently approved biologics, and countries are racing to claim their corner – or maintain their decades-old market share.
Expert insights. Personalized for you.
52 
Let's personalize your content